Progensa™ PCA3 test for prostate cancer detection

Expert Review of Molecular Diagnostics

Volumn 7, Issue 5, 2007, Pages 491-497

  De La Taille, Alexandre ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Biopsy; Incidence; PCA3; Prostate cancer; PSA

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CANCER DIAGNOSIS; CANCER RISK; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GOLD STANDARD; HUMAN; MOLECULAR BIOLOGY; NEEDLE BIOPSY; ONCOGENE; PCA3 GENE; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR CELL; BLOOD; GENE EXPRESSION REGULATION; GENETICS; INCIDENCE; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SPECIMEN HANDLING;

EID: 35148843620     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.5.491     Document Type: Review

References (33)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16, 481-488 (2005).
2. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States 2007: a review of current guidelines, practices, and prospects. CA Cancer J. Clin. 57, 90-104 (2007).
3. de la Taille A, Antiphon P, Salomon L et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 61(6), 1181-1186 (2003).
4. Bussemakers MJG, Van Bokhoven A, Verhaegh GW et al. DD3: A new prostate-specific gene, highly over-expressed in prostate cancer. Cancer Res. 59, 5975-5979 (1999).
5. De Kok JB, Verhaegh GW, Roelofs RW et al. DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62, 2695-2698 (2002).
6. Hessels D, Klein Gunnewiek MT, van Oort I et al. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 44, 8-16 (2003).
7. Van Gils MP, Cornel EB, Hessels D et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate. 67(8), 881-887 (2007).
8. Van Gils MP, Hessels D, van Hooij O et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 13(3), 939-943 (2007).
9. Hardick J, Giles J, Hardick A, Hsieh YH, Quinn T, Gaydos C. Performance of the Gen-Probe transcription-mediated amplification research assay compared to that of a multitarget real-time PCR for Mycoplasma genitalium. J. Clin. Microbiol. 44, 1236-1240 (2006).
10. Hardick A, Hardick J, Wood BJ, Gaydos C. Comparison between the Gen-Probe transcription-mediated amplification Trichomonas vaginalis research assay and real-time PCR for Trichomonas vaginalis detection using a Roche LightCycler instrument with female self-obtained vaginal swab samples and male urine samples. J. Clin. Microbiol. 44, 4197-4199 (2006).
11. Wroblewski JK, Manhart LE, Dickey KA, Hudspeth MK, Totten PA. Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium. J. Clin. Microbiol. 44, 3306-3312 (2006).
12. Meng FJ, Shan A, Jin L, Young CYF. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol. Biomarkers Prev. 11, 305-309 (2002).
13. Groskopf J, Aubin SM, Deras IL et al. APTIMA® PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem 52, 1089-1095 (2006).
14. Marks LS, Fradet Y, Deras IL et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69, 532-535 (2007).
15. Nakanishi H, Bhadkamkar V, Blase A et al. The relationship between PCA3 score and tumor volume in prostatectomy samples. Presented at: Journal of Clinical Oncology 2007 Multidisciplinary Prostate Cancer Symposium Program/Proceedings, American Society of Clinical Oncology. Orlando, FL, USA, 22-24 February 2007 (Abstract 354).
16. Groskopf J, Deras IL, Blase A et al. The PCA3 score is independent of prostate gland volume, and can synergize with other patient information for predicting biopsy outcome. Presented at: Journal of Urology 2007 Annual Meeting Program Abstracts, American Urological Association. Anaheim, CA, USA, 19-24 May 2007 (Abstract 1709).
17. Haese A, van Poppel H, Marberger M et al. The value of the PCA3 assay in guiding decision which men with a negative prostate biopsy need immediate repeat biopsy: preliminary European data. Presented at: European Urology Supplements, Annual European Association of Urology Congress. Berlin, Germany, 21-24 March 2007 (Abstract 101).
18. Partin AW, Carter HB, Mangold L et al. Biological variation of PCA3 score in men previously diagnosed with prostate cancer. Presented at: Journal of Urology 2007 Annual Meeting Program Abstracts, American Urological Association. Anaheim, CA, USA, 19-24 May 2007 (Abstract 1623).
19. Khan MA, Partin AW, Rittenhouse HG et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J. Urol. 170, 723-726 (2003).
20. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267, 2215-2220 (1992).
21. Djavan B, Zlotta A, Kratzik C et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 54, 517-522 (1999).
22. Gohji K, Nomi M, Egawa S et al. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer 79, 1969-1976 (1997).
23. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol. Clin. North Am. 20, 671-680 (1993).
24. Morgan TO, Jacobsen SJ, McCarthy WF et al. Age-specific reference ranges for serum prostate-specific antigen in black men. N. Engl. J. 335, 304-310 (1996).
25. Kwiatkowski MK, Recker F, Piironen T et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic 'gray zone' of total PSA 4 to 10 ng/ml. Urology 52, 360-365 (1998).
26. Leman ES, Cannon GW, Trock BJ et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69, 714-720 (2007).
27. Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H. Molecular markers for prostate cancer. Cancer Lett. 249, 5-13 (2007).
28. Crocitto LE, Korns D, Kretzner L et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 64, 821-825 (2004).
29. Sissi C, Lucatello L, Krapcho P et al. Tri-, tetra- and heptacyclic perylene analogues as new potential antineoplastic agents based on DNA telomerase inhibition. Bioorg. Med. Chem. 15, 555-562 (2007).
30. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 18, 161-170 (2007).
31. Chen YJ, Sheng WY, Huang PR, Wang TC. Potent inhibition of human telomerase by U-73122. J. Biomed. Sci. 13, 667-674 (2006).
32. Koeneman KS. Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype. Urol. Oncol. 24, 119-121 (2006).
33. Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, Uemura H. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int. J. Urol. 12, 73-80 (2005).